Table 3.
Performance of urinary biomarkers for prediction of acute kidney injury in COVID-19 patients.
| Biomarker | AUC | 95% CI | p | Cutoff | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|---|---|---|---|---|---|---|---|---|---|
| Prediction of AKI on day 1 | |||||||||
| EGF (pg/mL) | 0.788 | 0.597–0.979 | 0.014 | 4600 | 80.00 | 81.82 | 74.58 | 85.99 | 81.09 |
| [TIMP2] × [IGFBP7] (ng/mL)2/1000 |
0.672 | 0.521–0.823 | 0.036 | 0.2 | 42.86 | 95.65 | 86.79 | 71.52 | 74.53 |
| NGAL (ng/mL) | 0.797 | 0.668–0.927 | 0.014 | 40.0 | 68.00 | 73.91 | 63.47 | 77.60 | 71.55 |
Acute kidney injury (AKI); area under the receiver-operating characteristics curve (AUC); confidence interval (CI); positive predictive value (PPV); negative predictive value (NPV); neutrophil gelatinase-associated lipocalin (NGAL); tissue inhibitor of metalloproteinases-2 (TIMP-2); insulin-like growth factor binding protein 7 (IGFBP7).